ClinicalTrials.gg
CompletedNCT01710358RA-BEAMUpdated Sep 18, 2019Results posted

A Study in Moderate to Severe Rheumatoid Arthritis

A Phase 3 interventional study of Adalimumab and Baricitinib in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Completed at 213 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-18.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,307
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 23 studies testing baricitinib in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, 1 of them phase 3. baricitinib · Arthritis, Rheumatoid.

Enrollment
3rd of 23
1,307 · median 290
Started
2012
with 2 others
Phase 3
8 of 23
1 open now
Registered
5th of 23
by date
Lead sponsor
11 of 23
Eli Lilly and Company

Among the 23 studies testing baricitinib in Arthritis, Rheumatoid, this one is the 3rd largest by enrollment, is one of 3 that started in 2012, is one of 8 in phase 3, and was the 5th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 23 studies testing baricitinib in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About baricitinib

baricitinib: first FDA approval 2018 (OLUMIANT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing baricitinib in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether baricitinib is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had an inadequate response to methotrexate (MTX) treatment.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of adult-onset Rheumatoid Arthritis (RA) as defined by the American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) 2010 Criteria for the Classification of RA
  • Have moderately to severely active RA defined as the presence of at least 6/68 tender joints and at least 6/66 swollen joints
  • Have a C-reactive protein (CRP) or high-sensitivity C-reactive protein (hsCRP) measurement ≥6 milligram per Liter (mg/L)
  • Have had regular use of methotrexate (MTX) for at least the 12 weeks prior to study entry at a dose that is considered acceptable to adequately assess clinical response.
  • Have at least 1 joint erosion in hand, wrist, or foot joints based on radiographic interpretation by the central reader and be rheumatoid factor or anticyclic citrullinated peptide (anti-CCP) antibody positive; or have at least 3 joint erosions in hand, wrist, or foot joints based on radiographic interpretation by the central reader regardless of rheumatoid factor or anti-CCP antibody status

Exclusion criteria

Exclusion Criteria:

  • Are currently receiving at doses >10 mg of prednisone per day (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization
  • Have started treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or have been receiving an unstable dosing regimen of NSAIDs within 2 weeks of study entry or within 6 weeks of planned randomization
  • Are currently receiving concomitant treatment with MTX, hydroxychloroquine, and sulfasalazine or combination of any 3 conventional disease-modifying antirheumatic drugs (cDMARDs)
  • Are currently receiving or have received cDMARDs (eg, gold salts, cyclosporine, azathioprine, or any other immunosuppressives) other than MTX, hydroxychloroquine (up to 400 mg/day), or sulfasalazine (up to 3000 mg/day) within 4 weeks prior to study entry
  • Have received leflunomide in the 12 weeks prior to study entry
  • Have started a new physiotherapy treatment for RA in the 2 weeks prior to study entry
  • Have ever received any biologic disease-modifying antirheumatic drugs (DMARD)
  • Have received interferon therapy within 4 weeks prior to study entry or are anticipated to require interferon therapy during the study
  • Have received any parenteral corticosteroid administered by intramuscular or intravenous injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study
  • Have had 3 or more joints injected with intraarticular corticosteroids or hyaluronic acid within 2 weeks prior to study entry or within 6 weeks prior to planned randomization
  • Have any condition or for adalimumab that would preclude the participant from participating in this protocol
  • Have active fibromyalgia that would make it difficult to appropriately assess RA activity for the purposes of this study
  • Have a diagnosis of any systemic inflammatory condition other than RA such as, but not limited to, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, active vasculitis or gout(participants with secondary Sjögren's syndrome are not excluded)
  • Have a diagnosis of Felty's syndrome
  • Have had any major surgery within 8 weeks prior to study entry or will require major surgery during the study that, in the opinion of the investigator in consultation with Lilly or its designee, would pose an unacceptable risk to the participant
  • Have experienced any of the following within 12 weeks of study entry: myocardial infarction, unstable ischemic heart disease, stroke, or Stage IV heart failure
  • Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking product or could interfere with the interpretation of data
  • Are largely or wholly incapacitated permitting little or no self-care, such as being bedridden or confined to a wheelchair
  • have a history of, lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from for \<5 years
  • Have been exposed to a within 12 weeks prior to planned randomization or are expected to need/receive a live vaccine during the course of the study (with the exception of herpes zoster vaccination)
  • Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection
  • Have had symptomatic herpes zoster infection within 12 weeks prior to study entry
  • Have a history of disseminated/complicated herpes zoster (eg, multidermatomal involvement, ophthalmic zoster, central nervous system involvement, or postherpetic neuralgia)
  • Are and, in the opinion of the investigator, are at an unacceptable risk for participating in the study
  • Have a history of active virus (HBV), virus (HCV), or (HIV)
  • Have screening laboratory test values, including thyroid-stimulating hormone (TSH), outside the reference range for the population or investigative site that, in the opinion of the investigator, pose an unacceptable risk for the participant's participation in the study
  • Have screening (ECG) abnormalities that, in the opinion of the investigator or the sponsor, are clinically significant and indicate an unacceptable risk for the participant's participation in the study
  • Have symptomatic herpes simplex at the time of study enrollment
  • Have evidence of active or latent tuberculosis (TB)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,307 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo administered orally once daily through Week 24 and placebo administered by subcutaneous (SC) injection every 2 weeks through Week 50. At Week 24, participants were given baricitinib 4 milligram (mg) orally once daily through Week 52. Starting at Week 16, participants who were nonresponders were rescued with baricitinib 4 mg orally daily through Week 52. Participants continued to take background methotrexate (MTX) therapy throughout study.

    Drug: Methotrexate · Drug: Adalimumab Placebo · Drug: Baricitinib Placebo

  • Experimental
    Baricitinib

    Baricitinib 4 mg administered orally once daily through Week 52 and an adalimumab placebo SC injection every 2 weeks through Week 50. Starting at Week 16, nonresponder participants originally randomized to baricitinib continued to receive baricitinib 4 mg administered orally once daily through Week 52. Participants continued to take background methotrexate (MTX) therapy throughout study.

    Drug: Baricitinib · Drug: Methotrexate · Drug: Adalimumab Placebo

  • Active comparator
    Adalimumab

    Adalimumab 40 mg administered by SC injection every 2 weeks through Week 50 and baricitinib placebo orally once daily through Week 52. Starting at Week 16, participants who were nonresponders were rescued with baricitinib 4 mg orally once daily through Week 52. Participants continued to take background methotrexate (MTX) therapy throughout study.

    Drug: Adalimumab · Drug: Methotrexate · Drug: Baricitinib Placebo

Interventions

  • Administered SC

  • Administered orally

    Also known as: LY 3009104

  • Administered orally

  • DrugAdalimumab Placebo

    Adalimumab placebo administered SC.

  • DrugBaricitinib Placebo

    Baricitinib placebo administered orally.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20)

    ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). "ACR20 Responder" is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity using visual analog scale (VAS), Health Assessment Questionnaire-Disability Index (HAQ-DI), pain due to arthritis, and high-sensitivity C-reactive protein (hsCRP). Participants with missing responses and participants who discontinued study or drug or were rescued before analysis timepoint were deemed non-responders.

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline in the Modified Total Sharp Score (mTSS)

    X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448.

    Time frame: Baseline, Week 24

  2. Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

    The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty (0 \[without any difficulty\], 1 \[with some difficulty\], 2 \[with much difficulty\], and 3 \[unable to do\]) when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate the HAQ-DI score, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

    Time frame: Baseline, Week 12

  3. Change From Baseline in the Disease Activity Score Based on a 28-Joint Count and High-sensitivity C-reactive Protein (DAS28-hsCRP)

    Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), C-reactive protein (CRP) (milligrams per liter), and Patient's Global Assessment of Disease Activity using visual analog scale (VAS) (participant global VAS). DAS28 was calculated using following formula: DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*Patient's Global VAS+0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity.

    Time frame: Baseline, Week 12

  4. Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) and 70% (ACR70) Response

    ACR50 and ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. ACR50 and ACR70 Responder is a participant who has at least 50% or 70% improvement, respectively, in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinued study or drug or were rescued before analysis time point were deemed non-responders.

    Time frame: Week 12, Week 24, Week 52

  5. Change From Baseline in Clinical Disease Activity Index (CDAI) Score

    The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.

    Time frame: Baseline, Week 12, Week 24, Week 52

  6. Percentage of Participants Achieving Simplified Disease Activity Index (SDAI) Score ≤3.3

    SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using VAS centimeters (cm), and Physician's Global Assessment of Disease Activity using VAS (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. An index-based definition of remission occurs with an SDAI score ≤3.3.

    Time frame: Week 12, Week 24, Week 52

  7. Percentage of Participants Achieving American College of Rheumatology European League Against Rheumatism (ACR/EULAR) Remission - Boolean Remission

    The ACR/EULAR definitions of RA remission includes a Boolean-based definition. The Boolean-based definition of remission occurs when all 4 of the following criteria are met at the same visit: TJC28 ≤1, SJC28 ≤1, acute phase response using C-reactive protein (milligrams per deciliter) ≤1, Patient's Global Assessment of Disease Activity using VAS (cm) ≤1.

    Time frame: Week 12, Week 24, Week 52

  8. Median of Individual Participant Mean Duration of Morning Joint Stiffness in the Prior 7 Days as Collected in Electronic Diaries

    Participants recorded the duration of their morning joint stiffness (MJS) in hours and minutes into electronic diaries daily. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. The average value across the 7 days preceding each visit was calculated. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.

    Time frame: Week 12

  9. Mean Severity of Morning Joint Stiffness Numeric Rating Scale (NRS) in the Prior 7 Days as Collected in Electronic Diaries

    Participants rated the severity of their morning joint stiffness by selecting a number from 0 to 10 that best described their overall level of morning joint stiffness from the time they woke up, where 0 represents "no joint stiffness" and 10 represents "joint stiffness as bad as you can imagine". Participants reported their severity daily in electronic diaries. The average value across the 7 days preceding each visit was calculated.

    Time frame: Week 12

  10. Mean Worst Tiredness Numeric Rating Scale (NRS) in the Prior 7 Days as Collected in Electronic Diaries

    Participants rated their tiredness by selecting a number from 0 to 10 that best described their worst tiredness during the last 24 hours, where 0 represents "no tiredness" and 10 represents "as bad as you can imagine". Participants reported their worst tiredness in electronic diaries. The average value across the 7 days preceding each visit is calculated.

    Time frame: Week 12

  11. Mean Worst Joint Pain NRS in the Prior 7 Days as Collected in Electronic Diaries

    Participants rated their joint pain by selecting a number from 0 to 10 that best described their worst joint pain during the last 24 hours, where 0 represents "no pain" and 10 represents "pain as bad as you can imagine". Participants reported their worst joint pain in daily electronic diaries. The average value across the 7 days preceding each visit was calculated.

    Time frame: Week 12

  12. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale Scores

    The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale is a brief 13-item, symptom-specific questionnaire that specifically assesses the participant's self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 ("Not at all") to 4 ("Very much") for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.

    Time frame: Baseline, Week 12, Week 24, Week 52

  13. Change From Baseline in Mental Component Score (MCS), Physical Component Score (PCS) of the Medical Outcomes Study 36-Item Short Form Health Survey Version 2 Acute (SF-36v2 Acute)

    The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning.

    Time frame: Baseline, Week 12, Week 24, Week 52

  14. Change From Baseline in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores

    European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. One component consists of a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.

    Time frame: Baseline, Week 12, Week 24, Week 52

  15. Change From Baseline in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)

    A second component of the EQ-5D-5L is a self-perceived health score which is assessed using a VAS that ranges from 0 to 100 millimeter (mm), where 0 indicates the worst health you can imagine and 100 indicates the best health you can imagine.

    Time frame: Baseline, Week 12, Week 24, Week 52

  16. Change From Baseline in Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) Scores

    The Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. It contains 6 items covering overall work productivity (health), overall work productivity (symptom), impairment of regular activities (health), and impairment of regular activities (symptom). Scores are calculated as impairment percentages. The WPAI-RA yields four types of scores: Absenteeism (work time missed), Presenteeism (impairment at work), Work productivity loss (overall work impairment), and Activity impairment.

    Time frame: Baseline, Week 12, Week 24, Week 52

  17. Change From Baseline in Joint Space Narrowing (JSN) and Bone Erosion Scores

    X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing. The bone erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints, with 0 indicating no erosion and the highest score (5 for the hand and 10 for the foot) indicating extensive loss of bone from more than one half of the articulating bone. Erosion scores ranged from 0 (no erosion) to 280 (high erosion).

    Time frame: Baseline, Week 24, Week 52

  18. Population Pharmacokinetics (PK): Peak Concentration at Steady State (Cmax,ss) of Baricitinib

    Time frame: Week 0: 15 and 60 minutes postdose; Week 4: 2 to 4 hours post-dose; Week 8: 4 to 6 hours post-dose; Week 12; Week 12; Week 24; Week 32: Pre-dose

  19. Population PK: Area Under the Concentration Versus Time Curve at a Dosing Interval at Steady State (AUCtau,ss) of Baricitinib

    Time frame: Week 0: 15 and 60 minutes postdose; Week 4: 2 to 4 hours post-dose; Week 8: 4 to 6 hours post-dose; Week 12; Week 12; Week 24; Week 32: Pre-dose

07

Results

Posted Aug 15, 2017

Participant flow

Treatment Period Part A (Weeks 0 to 24)
Participant flow — Treatment Period Part A (Weeks 0 to 24)
MilestonePlaceboBaricitinibAdalimumab
Started489488330
Received at least 1 dose of study drug488487330
Rescued1283540
Completed438459307
Not completed512923
Withdrew: Adverse event15187
Withdrew: Death020
Withdrew: Entry criteria not met011
Withdrew: Lack of efficacy1513
Withdrew: Lost to follow-up010
Withdrew: Physician decision100
Withdrew: Sponsor decision400
Withdrew: Withdrawal by subject15512
Withdrew: Randomized but not treated110
Treatment Period Part B (Weeks 24 to 52)
Participant flow — Treatment Period Part B (Weeks 24 to 52)
MilestonePlaceboBaricitinibAdalimumab
Started310424267
Received at least 1 dose of study drug306424267
Rescued5811
Completed294402252
Not completed162215
Withdrew: Adverse event10165
Withdrew: Death101
Withdrew: Lack of efficacy001
Withdrew: Lost to follow-up001
Withdrew: Physician decision010
Withdrew: Sponsor decision120
Withdrew: Withdrawal by subject437
Rescue Period
Participant flow — Rescue Period
MilestonePlaceboBaricitinibAdalimumab
Started02270
Completed01960
Not completed0310
Withdrew: Adverse event0150
Withdrew: Death010
Withdrew: Lack of efficacy070
Withdrew: Withdrawal by subject080
Follow-up Period
Participant flow — Follow-up Period
MilestonePlaceboBaricitinibAdalimumab
Started337620
Completed337620
Not completed000

Outcome measures

PrimaryPercentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20)

ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). "ACR20 Responder" is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity using visual analog scale (VAS), Health Assessment Questionnaire-Disability Index (HAQ-DI), pain due to arthritis, and high-sensitivity C-reactive protein (hsCRP). Participants with missing responses and participants who discontinued study or drug or were rescued before analysis timepoint were deemed non-responders.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20)
percentage of participantsPlaceboBaricitinibAdalimumab
Percentage of Participants Achieving American College of Rheumatology 20% Improvement (ACR20)40.269.661.2
Statistical analysis
  • Placebo vs Baricitinib · Regression, Logistic · p = 0.001
SecondaryChange From Baseline in the Modified Total Sharp Score (mTSS)

X-rays of the hands/wrists and feet were scored for structural progression as measured using the mTSS. This methodology quantified the extent of bone erosions and joint space narrowing for 44 and 42 joints, with higher scores representing greater damage. The mTSS at a time point is the sum of the erosion (range from 0 to 280) and JSN (range from 0 to 168) scores, for a maximum score of 448.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in the Modified Total Sharp Score (mTSS)
units on a scalePlaceboBaricitinibAdalimumab
Change From Baseline in the Modified Total Sharp Score (mTSS)0.84 ± 2.320.35 ± 1.590.29 ± 1.47
SecondaryChange From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

The HAQ-DI questionnaire assesses the participant's self-perception on the degree of difficulty (0 \[without any difficulty\], 1 \[with some difficulty\], 2 \[with much difficulty\], and 3 \[unable to do\]) when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate the HAQ-DI score, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
units on a scalePlaceboBaricitinibAdalimumab
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score-0.33 ± 0.51-0.65 ± 0.59-0.56 ± 0.54
SecondaryChange From Baseline in the Disease Activity Score Based on a 28-Joint Count and High-sensitivity C-reactive Protein (DAS28-hsCRP)

Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), C-reactive protein (CRP) (milligrams per liter), and Patient's Global Assessment of Disease Activity using visual analog scale (VAS) (participant global VAS). DAS28 was calculated using following formula: DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*Patient's Global VAS+0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Disease Activity Score Based on a 28-Joint Count and High-sensitivity C-reactive Protein (DAS28-hsCRP)
units on a scalePlaceboBaricitinibAdalimumab
Change From Baseline in the Disease Activity Score Based on a 28-Joint Count and High-sensitivity C-reactive Protein (DAS28-hsCRP)-1.01 ± 1.12-2.27 ± 1.22-1.98 ± 1.28
SecondaryPercentage of Participants Achieving American College of Rheumatology 50% (ACR50) and 70% (ACR70) Response

ACR50 and ACR70 Responder Index is a composite of clinical, laboratory, and functional measures in RA. ACR50 and ACR70 Responder is a participant who has at least 50% or 70% improvement, respectively, in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, HAQ-DI, pain due to arthritis, and hsCRP. Participants with missing responses and participants who discontinued study or drug or were rescued before analysis time point were deemed non-responders.

Time frame:
Week 12, Week 24, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) and 70% (ACR70) Response
percentage of participantsPlaceboBaricitinibAdalimumab
ACR50 Week 1216.845.034.8
ACR50 Week 2419.350.545.5
ACR50 Week 52NA55.947.0
ACR70 Week 124.718.912.7
ACR70 Week 248.029.821.8
ACR70 Week 52NA37.230.6
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) Score

The CDAI is a tool for measurement of disease activity in RA that does not require a laboratory component and was scored by the investigative site. It integrates TJC28 (scored 0-28 with higher scores indicating higher disease activity), SJC28 (scored 0-28 with higher scores indicating higher disease activity), Patient's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity), and Physician's Global Assessment of Disease Activity (scored on a visual analogue scale from 0-10 cm with higher scores indicating higher disease activity). The CDAI is calculated by summing the values of the 4 components. CDAI scores range from 0 to 76; lower scores indicated lower disease activity. A negative change from baseline indicates improvement in condition.

Time frame:
Baseline, Week 12, Week 24, Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) Score
units on a scalePlaceboBaricitinibAdalimumab
Week 12-13.53 ± 13.88-23.00 ± 12.66-20.42 ± 13.47
Week 24-14.21 ± 15.13-25.04 ± 13.61-22.92 ± 14.63
Week 52NA ± NA-26.44 ± 14.42-23.48 ± 15.28
SecondaryPercentage of Participants Achieving Simplified Disease Activity Index (SDAI) Score ≤3.3

SDAI is a tool for measurement of disease activity in RA that integrates TJC28, SJC28, acute phase response using C-reactive protein (milligrams per liter), Patient's Global Assessment of Disease Activity using VAS centimeters (cm), and Physician's Global Assessment of Disease Activity using VAS (cm). The SDAI is calculated by summing the values of the 5 components. Lower scores indicated less disease activity. An index-based definition of remission occurs with an SDAI score ≤3.3.

Time frame:
Week 12, Week 24, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Simplified Disease Activity Index (SDAI) Score ≤3.3
percentage of participantsPlaceboBaricitinibAdalimumab
Week 121.88.47.3
Week 243.116.013.6
Week 52NA22.617.9
SecondaryPercentage of Participants Achieving American College of Rheumatology European League Against Rheumatism (ACR/EULAR) Remission - Boolean Remission

The ACR/EULAR definitions of RA remission includes a Boolean-based definition. The Boolean-based definition of remission occurs when all 4 of the following criteria are met at the same visit: TJC28 ≤1, SJC28 ≤1, acute phase response using C-reactive protein (milligrams per deciliter) ≤1, Patient's Global Assessment of Disease Activity using VAS (cm) ≤1.

Time frame:
Week 12, Week 24, Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology European League Against Rheumatism (ACR/EULAR) Remission - Boolean Remission
percentage of participantsPlaceboBaricitinibAdalimumab
Week 121.07.25.2
Week 242.712.110.0
Week 52NA15.613.0
SecondaryMedian of Individual Participant Mean Duration of Morning Joint Stiffness in the Prior 7 Days as Collected in Electronic Diaries

Participants recorded the duration of their morning joint stiffness (MJS) in hours and minutes into electronic diaries daily. If morning joint stiffness duration was longer than 12 hours (720 minutes), it was truncated to 720 minutes for statistical presentations and analyses. The average value across the 7 days preceding each visit was calculated. A decrease in duration of morning joint stiffness indicated an improvement in the participant's condition.

Time frame:
Week 12
Reported as:
Median · Minutes
Median of Individual Participant Mean Duration of Morning Joint Stiffness in the Prior 7 Days as Collected in Electronic Diaries
MinutesPlaceboBaricitinibAdalimumab
Median of Individual Participant Mean Duration of Morning Joint Stiffness in the Prior 7 Days as Collected in Electronic Diaries60.0 (60.0 to 75.0)27.1 (20.0 to 30.0)36.6 (30.0 to 45.7)
SecondaryMean Severity of Morning Joint Stiffness Numeric Rating Scale (NRS) in the Prior 7 Days as Collected in Electronic Diaries

Participants rated the severity of their morning joint stiffness by selecting a number from 0 to 10 that best described their overall level of morning joint stiffness from the time they woke up, where 0 represents "no joint stiffness" and 10 represents "joint stiffness as bad as you can imagine". Participants reported their severity daily in electronic diaries. The average value across the 7 days preceding each visit was calculated.

Time frame:
Week 12
Reported as:
Mean · units on a scale
Mean Severity of Morning Joint Stiffness Numeric Rating Scale (NRS) in the Prior 7 Days as Collected in Electronic Diaries
units on a scalePlaceboBaricitinibAdalimumab
Mean Severity of Morning Joint Stiffness Numeric Rating Scale (NRS) in the Prior 7 Days as Collected in Electronic Diaries4.1 ± 2.33.0 ± 2.23.4 ± 2.3
SecondaryMean Worst Tiredness Numeric Rating Scale (NRS) in the Prior 7 Days as Collected in Electronic Diaries

Participants rated their tiredness by selecting a number from 0 to 10 that best described their worst tiredness during the last 24 hours, where 0 represents "no tiredness" and 10 represents "as bad as you can imagine". Participants reported their worst tiredness in electronic diaries. The average value across the 7 days preceding each visit is calculated.

Time frame:
Week 12
Reported as:
Mean · units on a scale
Mean Worst Tiredness Numeric Rating Scale (NRS) in the Prior 7 Days as Collected in Electronic Diaries
units on a scalePlaceboBaricitinibAdalimumab
Mean Worst Tiredness Numeric Rating Scale (NRS) in the Prior 7 Days as Collected in Electronic Diaries4.4 ± 2.33.6 ± 2.23.9 ± 2.3
SecondaryMean Worst Joint Pain NRS in the Prior 7 Days as Collected in Electronic Diaries

Participants rated their joint pain by selecting a number from 0 to 10 that best described their worst joint pain during the last 24 hours, where 0 represents "no pain" and 10 represents "pain as bad as you can imagine". Participants reported their worst joint pain in daily electronic diaries. The average value across the 7 days preceding each visit was calculated.

Time frame:
Week 12
Reported as:
Mean · units on a scale
Mean Worst Joint Pain NRS in the Prior 7 Days as Collected in Electronic Diaries
units on a scalePlaceboBaricitinibAdalimumab
Mean Worst Joint Pain NRS in the Prior 7 Days as Collected in Electronic Diaries4.6 ± 2.23.4 ± 2.24.0 ± 2.3
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale Scores

The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale is a brief 13-item, symptom-specific questionnaire that specifically assesses the participant's self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 ("Not at all") to 4 ("Very much") for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.

Time frame:
Baseline, Week 12, Week 24, Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale Scores
units on a scalePlaceboBaricitinibAdalimumab
Week 126.8 ± 9.99.6 ± 10.49.5 ± 10.1
Week 246.6 ± 10.410.4 ± 10.89.9 ± 11.2
Week 52NA ± NA10.8 ± 10.99.8 ± 10.8
SecondaryChange From Baseline in Mental Component Score (MCS), Physical Component Score (PCS) of the Medical Outcomes Study 36-Item Short Form Health Survey Version 2 Acute (SF-36v2 Acute)

The SF-36 is a health-related survey that assesses participant's quality of life and consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \[MCS\] and physical \[PCS\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with higher scores indicating better health status or functioning.

Time frame:
Baseline, Week 12, Week 24, Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Mental Component Score (MCS), Physical Component Score (PCS) of the Medical Outcomes Study 36-Item Short Form Health Survey Version 2 Acute (SF-36v2 Acute)
units on a scalePlaceboBaricitinibAdalimumab
MCS Week 123.2 ± 10.33.3 ± 10.53.8 ± 10.8
MCS Week 242.2 ± 11.43.8 ± 10.93.9 ± 11.6
MCS Week 52NA ± NA4.0 ± 10.83.7 ± 11.2
PCS Week 124.3 ± 7.18.9 ± 8.17.6 ± 8.2
PCS Week 244.6 ± 7.89.9 ± 8.28.3 ± 9.1
PCS Week 52NA ± NA10.4 ± 9.09.0 ± 9.2
SecondaryChange From Baseline in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores

European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. One component consists of a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1, and the United States (US) algorithm, with scores ranging from -0.109 to 1. A higher score indicates better health state.

Time frame:
Baseline, Week 12, Week 24, Week 52
Reported as:
Mean · units on a scale
Change From Baseline in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores
units on a scalePlaceboBaricitinibAdalimumab
Index Score (US Algorithm) Week 120.073 ± 0.1510.132 ± 0.1560.130 ± 0.159
Index Score (US Algorithm) Week 240.065 ± 0.1680.143 ± 0.1680.137 ± 0.167
Index Score (US Algorithm) Week 52NA ± NA0.152 ± 0.1630.141 ± 0.189
Index Score (UK Algorithm) Week 120.107 ± 0.2210.188 ± 0.2280.186 ± 0.232
Index Score (UK Algorithm) Week 240.094 ± 0.2470.203 ± 0.2440.195 ± 0.245
Index Score (UK Algorithm) Week 52NA ± NA0.215 ± 0.2350.198 ± 0.273
SecondaryChange From Baseline in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)

A second component of the EQ-5D-5L is a self-perceived health score which is assessed using a VAS that ranges from 0 to 100 millimeter (mm), where 0 indicates the worst health you can imagine and 100 indicates the best health you can imagine.

Time frame:
Baseline, Week 12, Week 24, Week 52
Reported as:
Mean · millimeter
Change From Baseline in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)
millimeterPlaceboBaricitinibAdalimumab
Self-Perceived Health Week 127.9 ± 26.214.9 ± 25.810.7 ± 26.9
Self-Perceived Health Week 245.6 ± 27.117.5 ± 28.312.6 ± 28.9
Self-Perceived Health Week 52NA ± NA19.9 ± 28.013.3 ± 29.7
SecondaryChange From Baseline in Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) Scores

The Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) questionnaire was developed to measure the effect of general health and symptom severity on work productivity and regular activities in the 7 days prior to the visit. It contains 6 items covering overall work productivity (health), overall work productivity (symptom), impairment of regular activities (health), and impairment of regular activities (symptom). Scores are calculated as impairment percentages. The WPAI-RA yields four types of scores: Absenteeism (work time missed), Presenteeism (impairment at work), Work productivity loss (overall work impairment), and Activity impairment.

Time frame:
Baseline, Week 12, Week 24, Week 52
Reported as:
Mean · percentage of impairment
Change From Baseline in Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) Scores
percentage of impairmentPlaceboBaricitinibAdalimumab
Absenteeism Week 12 (n=160,168,118)0.5 ± 27.7-4.9 ± 20.6-0.5 ± 25.7
Absenteeism Week 24 (n=118,139,102)-1.6 ± 24.5-1.8 ± 25.2-3.2 ± 23.8
Absenteeism Week 52 (n=0,124,92)NA ± NA-3.8 ± 25.1-3.7 ± 24.3
Presenteeism Week 12 (n=147,160,113)-11 ± 23-21 ± 26-16 ± 24
Presenteeism Week 24 (n=110,134,99)-11 ± 22-23 ± 27-22 ± 26
Presenteeism Week 52 (n=0,119,88)NA ± NA-25 ± 27-25 ± 27
Work Productivity Loss Week 12 (n=147,160,113)-10.4 ± 24.3-21.6 ± 28.0-14.0 ± 25.6
Work Productivity Loss Week 24 (n=110,134,99)-9.0 ± 24.9-22.1 ± 30.2-21.4 ± 27.2
Work Productivity Loss Week 52 (n=0,119,88)NA ± NA-24.4 ± 30.1-24.6 ± 29.8
Activity Impairment Week 12 (n=458,474,315)-11 ± 25-25 ± 26-20 ± 25
Activity Impairment Week 24 (n=333,430,272)-16 ± 26-28 ± 27-26 ± 26
Activity Impairment Week 52 (n=0,396,240)NA ± NA-30 ± 27-28 ± 27
SecondaryChange From Baseline in Joint Space Narrowing (JSN) and Bone Erosion Scores

X-rays of the hands/wrists and feet were assessed for joint space narrowing (JSN) and bone erosions. Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including subluxation, is scored from 0 to 4, with 0 indicating no (normal) JSN and 4 indicating complete loss of joint space, bony ankylosis or luxation. JSN scores ranged from 0-168. A score of 0 would indicate no change and higher scores represent a worsening of joint space narrowing. The bone erosion score is a summary of erosion severity in 32 joints of the hands and 12 joints of the feet. Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for the foot joints, with 0 indicating no erosion and the highest score (5 for the hand and 10 for the foot) indicating extensive loss of bone from more than one half of the articulating bone. Erosion scores ranged from 0 (no erosion) to 280 (high erosion).

Time frame:
Baseline, Week 24, Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Joint Space Narrowing (JSN) and Bone Erosion Scores
units on a scalePlaceboBaricitinibAdalimumab
Joint Space Narrowing Week 24 (n= 452, 470, 312)0.27 ± 1.150.10 ± 0.740.09 ± 0.52
Joint Space Narrowing Week 52 (n= 452, 473, 312)0.56 ± 2.330.18 ± 1.020.17 ± 1.00
Bone Erosion Score Week 24 (n=452, 470, 312)0.57 ± 1.580.25 ± 1.120.20 ± 1.08
Bone Erosion Score Week 52 (n= 452, 473, 312)1.15 ± 3.210.42 ± 1.910.34 ± 2.00
SecondaryPopulation Pharmacokinetics (PK): Peak Concentration at Steady State (Cmax,ss) of Baricitinib
Time frame:
Week 0: 15 and 60 minutes postdose; Week 4: 2 to 4 hours post-dose; Week 8: 4 to 6 hours post-dose; Week 12; Week 12; Week 24; Week 32: Pre-dose
Reported as:
Geometric mean · nanomole/Liter (nmol/L)
Population Pharmacokinetics (PK): Peak Concentration at Steady State (Cmax,ss) of Baricitinib
nanomole/Liter (nmol/L)Baricitinib
Population Pharmacokinetics (PK): Peak Concentration at Steady State (Cmax,ss) of Baricitinib143 ± 19.7
SecondaryPopulation PK: Area Under the Concentration Versus Time Curve at a Dosing Interval at Steady State (AUCtau,ss) of Baricitinib
Time frame:
Week 0: 15 and 60 minutes postdose; Week 4: 2 to 4 hours post-dose; Week 8: 4 to 6 hours post-dose; Week 12; Week 12; Week 24; Week 32: Pre-dose
Reported as:
Geometric mean · nanomole*hr/Liter (nmol*hr/L)
Population PK: Area Under the Concentration Versus Time Curve at a Dosing Interval at Steady State (AUCtau,ss) of Baricitinib
nanomole*hr/Liter (nmol*hr/L)Baricitinib
Population PK: Area Under the Concentration Versus Time Curve at a Dosing Interval at Steady State (AUCtau,ss) of Baricitinib1220 ± 45.8

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Treatment A—26/488 (5.3%)177/488 (36.3%)
Baricitinib Treatment A—26/487 (5.3%)196/487 (40.2%)
Adalimumab Treatment A—7/330 (2.1%)132/330 (40%)
Placebo Treatment B—12/306 (3.9%)58/306 (19%)
BaricitinibTreatment B—16/424 (3.8%)70/424 (16.5%)
Adalimumab Treatment B—9/267 (3.4%)38/267 (14.2%)
Rescue—17/227 (7.5%)46/227 (20.3%)
Placebo Follow-up—2/33 (6.1%)3/33 (9.1%)
Baricitinib Follow-up—0/76 (0%)0/76 (0%)
Adalimumab Follow-up—0/20 (0%)3/20 (15%)
Most frequent serious events
Showing 10 of 112
Most frequent serious events
EventPlacebo Treatment ABaricitinib Treatment AAdalimumab Treatment APlacebo Treatment BBaricitinibTreatment BAdalimumab Treatment BRescuePlacebo Follow-upBaricitinib Follow-upAdalimumab Follow-up
PneumoniaInfections and infestations0/4881/4870/3301/3060/4240/2670/2271/330/760/20
Rheumatoid arthritisMusculoskeletal and connective tissue disorders4/4881/4870/3300/3061/4240/2670/2271/330/760/20
SepsisInfections and infestations0/4880/4870/3300/3060/4240/2671/2271/330/760/20
Respiratory failureRespiratory, thoracic and mediastinal disorders0/4880/4870/3300/3060/4240/2670/2271/330/760/20
AnaemiaBlood and lymphatic system disorders0/4882/4870/3300/3060/4240/2672/2270/330/760/20
EnterocolitisGastrointestinal disorders0/4880/4870/3300/3060/4240/2672/2270/330/760/20
FallInjury, poisoning and procedural complications0/4880/4870/3302/3060/4240/2670/2270/330/760/20
Urinary tract infectionInfections and infestations1/4880/4870/3300/3062/4240/2671/2270/330/760/20
Acute myocardial infarctionCardiac disorders0/4880/4870/3300/3061/4240/2671/2270/330/760/20
CholelithiasisHepatobiliary disorders1/4880/4870/3300/3060/4240/2671/2270/330/760/20
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPlacebo Treatment ABaricitinib Treatment AAdalimumab Treatment APlacebo Treatment BBaricitinibTreatment BAdalimumab Treatment BRescuePlacebo Follow-upBaricitinib Follow-upAdalimumab Follow-up
NasopharyngitisInfections and infestations35/48837/48734/33015/30624/42414/2679/2272/330/760/20
Upper respiratory tract infectionInfections and infestations14/48815/48713/33010/30613/4244/2676/2270/330/762/20
Ovarian cystReproductive system and breast disorders0/4880/4870/3300/3060/4240/2670/2270/330/761/16
Urinary tract infectionInfections and infestations16/48821/48713/3305/30610/4245/2675/2270/330/760/20
HeadacheNervous system disorders12/48814/48713/3300/3060/4240/2670/2270/330/760/20
BronchitisInfections and infestations14/48819/4878/33011/30612/4245/2676/2270/330/760/20
PharyngitisInfections and infestations14/48812/48712/33010/3064/4247/2675/2270/330/760/20
AnaemiaBlood and lymphatic system disorders15/48816/4874/3300/3060/4240/2678/2270/330/760/20
HypertensionVascular disorders13/4889/48711/3300/3060/4240/2670/2270/330/760/20
HypercholesterolaemiaMetabolism and nutrition disorders7/48815/4872/3300/3060/4240/2670/2270/330/760/20

Baseline characteristics

Modified Intent-to-Treat (mITT) population: all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboBaricitinibAdalimumabTotal
Mean53.4 ± 11.853.5 ± 12.252.9 ± 12.353.3 ± 12.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBaricitinibAdalimumabTotal
Female3823752511008
Male10611279297
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboBaricitinibAdalimumabTotal
American Indian or Alaska Native26191863
Asian148143101392
Native Hawaiian or Other Pacific Islander0000
Black or African American42410
White302312204818
More than one race711321
Unknown or Not Reported1001
Region of Enrollment
Region of Enrollment(Participants)PlaceboBaricitinibAdalimumabTotal
Argentina9110757255
Belgium2338
Canada54211
China21221154
Croatia1001
Czechia16101036
France88723
Germany0022
Greece1023
Hungary1811837
Japan939363249
South Korea21211557
Latvia2259
Lithuania4121026
Mexico503639125
Poland26351980
Portugal1113
Romania86216
Russia27282378
Slovakia88420
Slovenia4105
South Africa24211156
Spain1511531
Taiwan65718
United Kingdom2608
United States34362494
Duration of Rheumatoid Arthritis
Duration of Rheumatoid Arthritis(years)PlaceboBaricitinibAdalimumabTotal
Mean10.4 ± 8.710.3 ± 8.89.6 ± 8.510.1 ± 8.7
Tender Joint Count of 68 Evaluable Joints
Tender Joint Count of 68 Evaluable Joints(Number of Joints)PlaceboBaricitinibAdalimumabTotal
Mean23.3 ± 13.523.4 ± 13.023.4 ± 13.723.4 ± 13.3
Swollen Joint Count of 66 Evaluable Joints
Swollen Joint Count of 66 Evaluable Joints(Number of Joints)PlaceboBaricitinibAdalimumabTotal
Mean15.5 ± 9.415.0 ± 8.215.4 ± 9.115.3 ± 8.9
High Sensitivity C-Reactive Protein (hsCRP)
High Sensitivity C-Reactive Protein (hsCRP)(milligrams per liter (mg/L))PlaceboBaricitinibAdalimumabTotal
Mean19.66 ± 20.9722.20 ± 22.8521.78 ± 20.8321.14 ± 21.67
08

Study locations

213 sites
  • Arizona Arthritis & Rheumatology Research
    Glendale, Arizona 85304, United States
  • Sun Valley Arthritis Center, LTD
    Peoria, Arizona 85381, United States
  • Valley Arthritis Care, LLC
    Phoenix, Arizona 85023, United States
  • University of Boards Regent
    Tucson, Arizona 85724, United States
  • Valley Endocrine, Fresno
    Fresno, California 93720, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • Pacific Arthritis Center
    Santa Maria, California 93454, United States
  • Inlande Rheumatology Clinical Trials
    Upland, California 91786, United States
  • Boulder Medical Center
    Boulder, Colorado 80304, United States
  • Clinical Research Center of CT/NY
    Danbury, Connecticut 06810, United States
  • New England Research Associates
    Trumbull, Connecticut 06611, United States
  • Delaware Arthritis
    Lewes, Delaware 19958, United States
  • Orthopedic Research Institute
    Boynton Beach, Florida 33472, United States
  • Jeffrey Alper, M.D.
    Naples, Florida 34102, United States
  • Sun Coast Clinical Research, Inc
    New Port Richey, Florida 34652, United States
  • Rheumatology Associates of Central Florida
    Orlando, Florida 32806, United States
  • Integral Rheumatology & Immunology Specialists
    Plantation, Florida 33324, United States
  • McIlwain Medical Group
    Tampa, Florida 33613, United States
  • Indiana University Health
    Indianapolis, Indiana 46202, United States
  • Diagnostic Rheumatology and Research
    Indianapolis, Indiana 46227, United States
  • Goldpoint Clinical Research LLC
    Indianapolis, Indiana 46260, United States
  • West Michigan Rheumatology
    Grand Rapids, Michigan 49546, United States
  • University of Missouri
    Columbia, Missouri 65212, United States
  • Dr. George Timothy Kelly
    Las Vegas, Nevada 89128, United States
  • (AOA) Arthritis & Osteoporosis Associates
    Freehold, New Jersey 07728, United States
  • Bio Behavioral Health
    Toms River, New Jersey 08755, United States
  • Drug Trials of America
    Hartsdale, New York 10530, United States
  • Asheville Rheumatology & Osteoporosis Research Assoc, PA
    Asheville, North Carolina 28803, United States
  • Paramount Medical Research
    Middleburg Heights, Ohio 44130, United States
  • Health Research Institute
    Oklahoma City, Oklahoma 73103, United States
  • Healthcare Research Consultant
    Tulsa, Oklahoma 74135, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • East Penn Rheumatology
    Bethlehem, Pennsylvania 18017, United States
  • Clinical Research Center of Reading, LLP
    Wyomissing, Pennsylvania 19610, United States
  • Carolina Rheumatology and Neurology Associates
    Myrtle Beach, South Carolina 29572, United States
  • Metroplex Clinical Research Center
    Dallas, Texas 75231, United States
  • Pioneer Research Solutions
    Houston, Texas 77008, United States
  • Accurate Clinical Research
    Houston, Texas 77084, United States
  • Arthritis & Osteoporosis Associates LLP
    Lubbock, Texas 79424, United States
  • Accurate Clinical Research
    Nassau Bay, Texas 77058, United States
  • Accurate Clinical Research
    Webster, Texas 77508, United States
  • Center for Arthritis and Rheumatic Diseases, PC
    Chesapeake, Virginia 23320, United States
  • The Seattle Arthritis Clinic
    Seattle, Washington 98133, United States
  • Vancouver Clinic
    Vancouver, Washington 98664, United States
  • Rheumatology and Immunotherapy Center
    Franklin, Wisconsin 53132, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bahia Blanca, B8000HXM, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, CBA 1419, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Caba, C1440AAD, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Córdoba, 5000, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mar Del Plata, B7600FZN, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Quilmes, B1878DVC, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rosario, 2000, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Fernando, 1646, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, 5400, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Miguel De Tucuman, T4000AXL, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brussel, 1200, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Genk, 3600, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Merksem, 2170, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mons, 7000, Belgium
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kelowna, British Columbia V1Y3G8, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Victoria, British Columbia V8V 3P9, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kitchener, Ontario N2M 5N6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St. Catherines, Ontario L2N 7E4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toronto, Ontario M5T 3L9, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Trois-Rivieres, Quebec G8Z 1Y2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100044, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bengbu, 233004, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changsha, 410011, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guang Zhou, 510630, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hefei, 230022, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jinan, 250012, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 200052, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wu Han, 430030, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Varazdin, 42000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zagreb, 10 000, Croatia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brno, 61141, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bruntal, 79201, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hustopece, 693 01, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ostrava - Trebovice, 722 00, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ostrava, 702 00, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pardubice, 530 02, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Prague, 128 50, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Uherske Hradiste, 686 01, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Zlin, 760 01, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cahors Cedex 9, 46005, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Limoges, 87042, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montpellier, 34295, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nantes, 44093, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orleans, 45032, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paris, 75679, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Poitiers, 86021, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Strasbourg, 67098, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Thionville, 57100, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tours, 37044, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gommern, 39245, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Herne, 44649, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Köln, 50937, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Würzburg, 97080, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Athens, 11527, Greece
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Heraklion, 71110, Greece

Showing the first 100 of 213 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Taylor PC, Takeuchi T, Burmester GR, Durez P, Smolen JS, Deberdt W, Issa M, Terres JR, Bello N, Winthrop KL. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. 2022 Mar;81(3):335-343. doi: 10.1136/annrheumdis-2021-221276. Epub 2021 Oct 27. PubMed 34706874 ↗
  • van der Heijde D, Kartman CE, Xie L, Beattie S, Schlichting D, Mo D, Durez P, Tanaka Y, Fleischmann R. Radiographic Progression of Structural Joint Damage Over 5 Years of Baricitinib Treatment in Patients With Rheumatoid Arthritis: Results From RA-BEYOND. J Rheumatol. 2022 Feb;49(2):133-141. doi: 10.3899/jrheum.210346. Epub 2021 Sep 15. PubMed 34526397 ↗
  • Emery P, Tanaka Y, Cardillo T, Schlichting D, Rooney T, Beattie S, Helt C, Smolen JS. Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis. Arthritis Res Ther. 2020 May 15;22(1):115. doi: 10.1186/s13075-020-02199-8. Erratum In: Arthritis Res Ther. 2020 Jul 2;22(1):166. doi: 10.1186/s13075-020-02257-1. PubMed 32414425 ↗
  • Schlueter M, Finn E, Diaz S, Dilla T, Inciarte-Mundo J, Fakhouri W. Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain. Clinicoecon Outcomes Res. 2019 Jun 6;11:395-403. doi: 10.2147/CEOR.S201621. eCollection 2019. PubMed 31239736 ↗
  • Michaud K, Pope JE, Emery P, Zhu B, Gaich CL, DeLozier AM, Zhang X, Dickson CL, Smolen JS. Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial. Rheumatol Ther. 2019 Sep;6(3):409-419. doi: 10.1007/s40744-019-0164-4. Epub 2019 Jun 21. PubMed 31228100 ↗
  • Tanaka Y, Fautrel B, Keystone EC, Ortmann RA, Xie L, Zhu B, Issa M, Patel H, Gaich CL, de Bono S, Rooney TP, Taylor PC. Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis. Ann Rheum Dis. 2019 Jul;78(7):890-898. doi: 10.1136/annrheumdis-2018-214529. Epub 2019 Apr 30. PubMed 31040122 ↗
  • Bingham CO 3rd, Gaich CL, DeLozier AM, Engstrom KD, Naegeli AN, de Bono S, Banerjee P, Taylor PC. Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation. Trials. 2019 Mar 22;20(1):182. doi: 10.1186/s13063-019-3272-0. Erratum In: Trials. 2019 Jun 4;20(1):322. doi: 10.1186/s13063-019-3463-8. PubMed 30902094 ↗
  • Combe B, Balsa A, Sarzi-Puttini P, Tony HP, de la Torre I, Rogai V, Durand F, Witt S, Zhong J, Dougados M. Efficacy and safety data based on historical or pre-existing conditions at baseline for patients with active rheumatoid arthritis who were treated with baricitinib. Ann Rheum Dis. 2019 Aug;78(8):1135-1138. doi: 10.1136/annrheumdis-2018-214261. Epub 2019 Mar 6. No abstract available. PubMed 30842122 ↗
  • Smolen JS, Genovese MC, Takeuchi T, Hyslop DL, Macias WL, Rooney T, Chen L, Dickson CL, Riddle Camp J, Cardillo TE, Ishii T, Winthrop KL. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment. J Rheumatol. 2019 Jan;46(1):7-18. doi: 10.3899/jrheum.171361. Epub 2018 Sep 15. Erratum In: J Rheumatol. 2019 Dec;46(12):1648-1649. doi: 10.3899/jrheum.171361.C1. PubMed 30219772 ↗
  • Tanaka Y, McInnes IB, Taylor PC, Byers NL, Chen L, de Bono S, Issa M, Macias WL, Rogai V, Rooney TP, Schlichting DE, Zuckerman SH, Emery P. Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis. Arthritis Rheumatol. 2018 Dec;70(12):1923-1932. doi: 10.1002/art.40680. Epub 2018 Oct 22. PubMed 30058112 ↗
  • Wells AF, Greenwald M, Bradley JD, Alam J, Arora V, Kartman CE. Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis. Rheumatol Ther. 2018 Jun;5(1):43-55. doi: 10.1007/s40744-018-0110-x. Epub 2018 Apr 21. PubMed 29680881 ↗
  • Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, Chen L, Witt S, Saifan C, Kurzawa M, Otvos JD, Connelly MA, Macias WL, Schlichting DE, Rooney TP, de Bono S, McInnes IB. Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies. Ann Rheum Dis. 2018 Jul;77(7):988-995. doi: 10.1136/annrheumdis-2017-212461. Epub 2018 Feb 20. PubMed 29463520 ↗
  • Keystone EC, Taylor PC, Tanaka Y, Gaich C, DeLozier AM, Dudek A, Zamora JV, Cobos JAC, Rooney T, Bono S, Arora V, Linetzky B, Weinblatt ME. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Ann Rheum Dis. 2017 Nov;76(11):1853-1861. doi: 10.1136/annrheumdis-2017-211259. Epub 2017 Aug 10. PubMed 28798049 ↗
  • Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345. PubMed 28199814 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Mar 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 2 years 5 months after primary completion. A results delay was requested in May 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2012
First posted
Oct 19, 2012
Start
Oct 2012
Primary completionActual
Mar 2015
CompletionActual
Sep 2015
Results delay requested
May 8, 2015
Results first posted
Aug 15, 2017
Last update
Sep 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01710358
Responsible party
Sponsor
First posted
Oct 19, 2012
Start date
Oct 2012
Primary completion
Mar 2015
Completion
Sep 2015
Results posted
Aug 15, 2017
Last update
Sep 18, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion